Platelet Prostaglandins and Related Compounds in Diabetes Mellitus
Diabetic patients show a thrombotic tendency with an increase of platelet functions (for a review see reference 1). Prostaglandins and thromboxanes are produced during platelet activation and some of those are potent pro-aggregatory molecules (2, 3). Recently, some investigators have found that diabetic platelet-rich plasmas produce more prostaglandin E-like material than normal platelets when they are aggregated (4). Otherwise, platelets obtained from diabetic subjects are less sensitive to the antiaggregatory effects of imidazole, a thromboxane synthesis inhibitor (5).
KeywordsPlatelet Aggregation Thrombotic Tendency Antiaggregatory Effect Thrombin Stimulation Radiochemical Technique
Unable to display preview. Download preview PDF.
- 2.B. Samuelsson, M. Hamberg, C. Malmsten and J. Svensson, The role of prostaglandin endoperoxides and thromboxanes in platelet aggregation. In: Advances in prostaglandin and thromboxane research. Samuelsson, B. and Paoletti, R. (Eds). New York. Raven Press. 1976, 2, 763–766.Google Scholar
- 3.J.B. Smith, C.M. Ingerman and M.J. Silver, Effects of arachidonic acid and some of its metabolites on platelets. In: Prostaglandins in haematology. Silver, M.J., Smith, J.B. and Kocsis, J.J. (Eds). New York. Spectrum Publications. 1977, 155.Google Scholar
- 6.M. Lagarde, P.A. Bryon, M. Guichardant and M. Dechavanne, A simple method for platelet isolation from their plasma. Thrombos. Res. In press.Google Scholar
- 9.M. Lagarde, B. Velardo, M. Blanc and M. Dechavanne, Fatty acids bound to serum albumin decrease the half-life of thromboxane A2. Submitted for publication.Google Scholar
- 12.R.R. Gorman and O.V. Miller, Modulation of platelet cyclic nucleotide levels by PGE1 and the prostaglandin endoperoxides PGG2 and PGH1. In: Prostaglandins in hematology. Silver, M. J., Smith, J.B. and Kocsis, J.J. (Eds). New York. Spectrum Publications. 1977, 235–246.Google Scholar